Trial
NCT04012255
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novo Nordisk A/S
Collaborators
—
Condition
Overweight
Intervention
Semaglutide (administered by DV3396 pen)
Why stopped
The trial was terminated for strategic reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-23